{"name":"Xentria, Inc.","slug":"xentria-inc","ticker":"","exchange":"","domain":"xentria.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"US-Humalog®","genericName":"US-Humalog®","slug":"us-humalog","indication":"Other","status":"phase_1"},{"name":"US-Lantus®","genericName":"US-Lantus®","slug":"us-lantus","indication":"Other","status":"phase_1"},{"name":"US-NovoLog®","genericName":"US-NovoLog®","slug":"us-novolog","indication":"Other","status":"phase_1"},{"name":"US-Prolia®","genericName":"US-Prolia®","slug":"us-prolia","indication":"Other","status":"phase_1"},{"name":"XTMAB-16","genericName":"XTMAB-16","slug":"xtmab-16","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"US-Humalog®","genericName":"US-Humalog®","slug":"us-humalog","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"US-Lantus®","genericName":"US-Lantus®","slug":"us-lantus","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"US-NovoLog®","genericName":"US-NovoLog®","slug":"us-novolog","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"US-Prolia®","genericName":"US-Prolia®","slug":"us-prolia","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"XTMAB-16","genericName":"XTMAB-16","slug":"xtmab-16","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxNamNjSHZhTnhfM3JfS2tGeWxsN0ZuN2FJRkxZaW9LbUR2dVp3TTZRdmVkcUZHODZZUHkxclFKbEhKSEpIZXM4QmpTc0tyakpjYXhkRjRjem5ZVXpwaU9ET1lUZlVfSk92WEhjRzBlVVFiNlVjZ0ZlVXlwUzRCdW5xb1Q3Mkx3WHFBTmstZzBlRVNzMVlYR1RITDF0YWtUM1R0UEhyeVY0cjZlS2ZsVTVmWFh5WGhVOEgtZmVwVkVKSVdMcEVQRl84LTZ2T1hlUlVRbERGbHdacjdERXVOSVNWcVltTnhCSDR3TnlQc2t0RlFqd2h0RlpDbg?oc=5","date":"2025-05-22","type":"earnings","source":"prnewswire.com","summary":"Xentria Launches Xturnpoint to Fuel Early-Stage Therapeutic Innovation, Expands Headquarters to Support Growth - prnewswire.com","headline":"Xentria Launches Xturnpoint to Fuel Early-Stage Therapeutic Innovation, Expands Headquarters to Support Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQcndSOGgyLWZ2VFR3cmx3VDF4VWswSnA2VXdFRHRPb3RRMEZrVTVmbkIwemlQeHltemhzNm9ISk5GMS1uOFI4WjZad3p5aXVvZl9uMTJPXzlLblMyX1Z3Q2ZLZjFzOWl1dC1fZko5VUtLeEt3cWNNSkNLTlZ4UTdvZ0JsalduRnNOVVVkTWh2ZUE1YlNQNlkwR1djdTN2Z2ZEQXdGS29UNEw5dlhwdlpLQVBSUXJ5MmQyZHNFQkktOTY4aDhqeGFoSnFwaERsVnQ0aGpr?oc=5","date":"2025-01-08","type":"patent","source":"prnewswire.com","summary":"Expanding Horizons: Xentria Achieves Milestone Success with Biosimilar Development - prnewswire.com","headline":"Expanding Horizons: Xentria Achieves Milestone Success with Biosimilar Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxPYnVMWFdBT0h2M0NnNHRZckZkV1B0cEQ1LWNWSUxpUjBmWUZpa1ZmUUdDaDFGNU5jZS1lbHVVWnNmYW5SOVdxeHdTQWZfS29DZ3B0Yjk4X2ZTT2Uxa21xY1lidWN4QzFqd29tMWdwMGZLcms5VFNVT2pPTHB1TkQ5cUljaVVTdFBwSkFaTHdjc21UZS13QXR1dy04WW9hMmpVczNPWFlsdHZXMk0xQnl6QkNZOXZzRlU0eUYzQnZENmUyT0M0Mm9CZUZJajg1Q0s3S3p5ZzAyVUc3cDFwc09Oa19iQ1ZRZ0s4WllDOVQ2X09abDM4bDZ1ckNydmdzNmpYc2dRNUJmRWJhTXpaRFQ5cGdSQ1o1UkQxaTNV?oc=5","date":"2024-12-19","type":"pipeline","source":"prnewswire.com","summary":"Xentria Announces Exclusive Licensing Agreement with New York University to Advance a Disease-Modifying Cardiovascular Therapy Globally - prnewswire.com","headline":"Xentria Announces Exclusive Licensing Agreement with New York University to Advance a Disease-Modifying Cardiovascular T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNaWxEcTd0SDV6S2ZlTW0tMHBHX1ZKNmcxamRTdnNBSnlldllVU2hKRFQ5SzFuNjQ2UzlfdW9hbmhMWTJzME1KRUlTR1EyMloteTNMWm5GN01lZ09Qc2preGhIeDN5czE4N1M1dS1CbVNxd0tFRC0wYzdEU21pMkR0anlRSGJOQQ?oc=5","date":"2023-06-28","type":"deal","source":"Pharmaceutical Technology","summary":"Xentria and Meitheal enter sarcoidosis therapy licensing deal - Pharmaceutical Technology","headline":"Xentria and Meitheal enter sarcoidosis therapy licensing deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxOeGMtZ3lVTG9pdHJKMXNMaGczaFJGQThoeHlxeUxhd0dRNXlOd1dudnBVcG9vR1NLQWhWV0pzUHRCX09IcmE1U1B5RHB0V1RqM2M2UHpMMFRUemIzczY0OUZrdHV0Nzd0TWZwT0ExTkYxTnUxbXFWRzQ3am9OT25acWxxYmp1YUh2ZzJQN3JGNW5fUnlTeFhOVXlhd1RSVmtfejlPVXdBZzFwNWVGSTVlQUpza0Y5djR1OVBmV0drVUhjMUg1dHVPeGViQ0VaR0NCSU1YWms1VE9xTjJEcXVmNWV1ZTMyckdraEhfWTN0YnphUTNj?oc=5","date":"2023-06-27","type":"pipeline","source":"businesswire.com","summary":"Xentria and Meitheal Pharmaceuticals Announce Exclusive Licensing Agreement for XTMAB-16 in North America - businesswire.com","headline":"Xentria and Meitheal Pharmaceuticals Announce Exclusive Licensing Agreement for XTMAB-16 in North America","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQTExnZnhPUENBY0RRU1RoV0x4VlhiTWdoWXFUZ1BpdTYxczRiUWdCRGxkNEoxT1YzbHJhMnN6b3g2YmtRQUR6TUd1c0RpQllkNjEwajA4Znd3UlVUczBGZnpfRUhjRzJRRnNmUEVTZXFXTXRZbjNYOG5kS0E4OV9hRnY3bVc0eWFDTGN0R0k0dFRacVYwZFpuYmZ3MkNhSmttMUJmTFVULU4yeXRZSkJhSGlRQzVRRFdud1VFa3lMUQ?oc=5","date":"2023-06-27","type":"pipeline","source":"Fierce Biotech","summary":"Meitheal bets there is still life in TNF inhibitors, paying Xentria $45M for lung disease therapy - Fierce Biotech","headline":"Meitheal bets there is still life in TNF inhibitors, paying Xentria $45M for lung disease therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxOdGdPSlVpN09tV0t1WXNVRW8yNGQyUnVXbTBfckw5Z25uNlpjSDh6dDZHNzN1ZlNEZzNXZXM3eV9SenJOUm9pRTdGbVl1Uko5UGV0bm9IRWRnN2lORlltcE13d3ZRckdXWjBWYXZ6bUpEdFhQNjhBRkhRTTI5dTByOWpoZW5MbHpLMTl5WGVacEJ1VlFDVVBjUlhLX1RhWDJSTS1XNUdtSk93LV94OW4xRXF2VUxuYnRIcXltd1pHMGZRS0ZrYWNKRFRQSmxMdlFaTEpCcVVQUVR4b0k1MHZtT0YwUG5Ydm91TTVEQU13Y1pEZw?oc=5","date":"2023-03-21","type":"pipeline","source":"businesswire.com","summary":"Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal - businesswire.com","headline":"Xentria Announces Peer Reviewed Publication of Biosimulation Model in Frontiers in Pharmacology Journal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxONlhXZ1hOY3J0bUJMZlMtWFVYNFAwcjBpQ2hZRDFQcXpYd01nb0t2WjN3LVFyX2RhUFktcXl1XzRSbTUxTkpzZFZxMUV5Sl9lOGcwSXVLMVh1M2w0NDVmTy1SVEhmSG9ZNzNTVkhZS2V2RWtUZk45c3JtZ2FxbzBmOUwtMlA4NlpGT0FNcVJROA?oc=5","date":"2022-10-19","type":"pipeline","source":"The Business Journals","summary":"Xentria joins other biotech startups in Chicago's Lincoln Yards - The Business Journals","headline":"Xentria joins other biotech startups in Chicago's Lincoln Yards","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQTGNHV3V6QjhDUkR3cEYyS3hZWEFiX1A5elo1S1M3UlNxX1Jqc1ducHB6eXh4MThrUmVqek9ER3lXMTRGZDBOVFl4UmgwZm1US3FSaUZOOTRUWG1RNzcyZ21ZRUMwSDYxZ2FxMXMxWnFQYkxfcUhOcGw1Ni1URG5palNQQ1lUWERhTlBGNlFhRlhmTS1JaWtZZExyOVE1ZWttU0xZ0gGoAUFVX3lxTE4yZmd6MEJjb1oxM2lhMWRoY000b1lGR3pwNnhpUGV5eWZUZUs3dldZOThKX21wTmduLXdva19oTURYVVZLdlczdkNkV2kxdmJKSzRZVXRVYWxaMnhUUVRDZEtQR3l0aWs3TGlXajAxUGwyTWRHVHFRYm9HVXgwR20xYy1ZazN6QVNkX24yb2VwdU0zRFYtZnZ4WFZtOXFzU3dtcm9qdXVsVg?oc=5","date":"2020-12-15","type":"regulatory","source":"Express Pharma","summary":"Xentria gets US FDA orphan drug designation for XTMAB-16 in sarcoidosis - Express Pharma","headline":"Xentria gets US FDA orphan drug designation for XTMAB-16 in sarcoidosis","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_1":4,"phase_2":1},"enrichmentLevel":0,"visitCount":7,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}